MAIN STORY
A large agreement with conditional payments
Rona Therapeutics announced on October 13, 2026 that it had entered a licensing agreement with Roche for an investigational obesity candidate, according to Reuters. The Chinese biotechnology company is set to receive $100 million upfront, is eligible for up to $1.06 billion in milestones and will receive tiered royalties on global net sales. The structure distinguishes the initial payment from amounts that may arise later, depending on the relevant conditions.
The maximum $1.16 billion should therefore not be presented as money already paid or guaranteed drug revenue. Royalties are separately mentioned in the reference, which does not specify their rates. A large headline indicates potential commercial commitment without establishing scientific success. Understanding the transaction requires following both the development arrangements and actual progress. Conditional payments also mean that the final amount can differ from the maximum described when the agreement is announced.















